{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:56Z","timestamp":1792510976863,"version":"4.5.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcrc.2025.155207","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T03:53:02Z","timestamp":1753761182000},"page":"155207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ceftazidime-avibactam plus aztreonam for extensively drug-resistant gram-negative infections in critically ill patients"],"prefix":"10.1016","volume":"90","author":[{"given":"Debasish","family":"Biswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankhuri","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ripenmeet","family":"Salhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.jcrc.2025.155207_bb0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"4\u20135","key":"10.1016\/j.jcrc.2025.155207_bb0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drup.2010.05.002","article-title":"Resistance to polymyxins: mechanisms, frequency and treatment options","volume":"13","author":"Falagas","year":"2010","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.1016\/j.jcrc.2025.155207_bb0015","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and Aztreonam overcome \u03b2-lactam resistance conferred by Metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jcrc.2025.155207_bb0020","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00472-17","article-title":"In vitro activity of Aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015","volume":"61","author":"Karlowsky","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jcrc.2025.155207_bb0025","doi-asserted-by":"crossref","first-page":"e00010","DOI":"10.1128\/AAC.00010-19","article-title":"Aztreonam plus clavulanate, tazobactam, or avibactam for treatment of infections caused by metallo-\u03b2-lactamase-producing gram-negative Bacteria","volume":"63","author":"Emeraud","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jcrc.2025.155207_bb0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.jcrc.2025.155207_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2025.155207_bb0040","doi-asserted-by":"crossref","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.jcrc.2025.155207_bb0045","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/jac\/dkv094","article-title":"Activity of ceftazidime\/avibactam against isogenic strains of Escherichia coli containing KPC and SHV \u03b2-lactamases with single amino acid substitutions in the \u03a9-loop","volume":"70","author":"Winkler","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jcrc.2025.155207_bb0050","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/21505594.2017.1292196","article-title":"Therapeutic options for carbapenem-resistant Enterobacteriaceae infections","volume":"8","author":"Trecarichi","year":"2017","journal-title":"Virulence"},{"issue":"9","key":"10.1016\/j.jcrc.2025.155207_bb0055","doi-asserted-by":"crossref","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","article-title":"Ceftazidime-avibactam and Aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by Metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa","volume":"61","author":"Davido","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jcrc.2025.155207_bb0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/jac\/dkx496","article-title":"Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection","volume":"73","author":"Shaw","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jcrc.2025.155207_bb0065","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.jcrc.2025.155207_bb0070","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious diseases society of America guidance on the treatment of AmpC \u03b2-lactamase-producing enterobacterales, carbapenem-resistant acinetobacter baumannii, and stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jcrc.2025.155207_bb0075","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cmi.2017.08.030","volume":"24","author":"Bassetti","year":"2018","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944125001947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944125001947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:56:33Z","timestamp":1792508193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944125001947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"alternative-id":["S0883944125001947"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2025.155207","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftazidime-avibactam plus aztreonam for extensively drug-resistant gram-negative infections in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2025.155207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"155207"}}